• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].

作者信息

Wang X, Bao X B, Zhang J, Song B Q, Li M Y, Xie J D, Shen H J, Wu D P, Qiu H Y

机构信息

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):691-694. doi: 10.3760/cma.j.issn.0253-2727.2022.08.014.

DOI:10.3760/cma.j.issn.0253-2727.2022.08.014
PMID:36709157
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9593004/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/319b/9593004/238d449eb86d/cjh-43-08-691-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/319b/9593004/238d449eb86d/cjh-43-08-691-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/319b/9593004/238d449eb86d/cjh-43-08-691-g001.jpg

相似文献

1
[Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].Bcl-2抑制剂维奈克拉联合方案治疗30例IDH1/2突变急性髓系白血病的临床分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):691-694. doi: 10.3760/cma.j.issn.0253-2727.2022.08.014.
2
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.艾伏尼布诱导的分化增强了异柠檬酸脱氢酶2（IDH2）突变的急性髓系白血病对维奈克拉的敏感性。
Leukemia. 2022 Mar;36(3):869-872. doi: 10.1038/s41375-021-01468-y. Epub 2021 Nov 6.
3
A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.一种针对急性髓系白血病中突变异柠檬酸脱氢酶的合成致死方法。
Nat Med. 2015 Feb;21(2):113-4. doi: 10.1038/nm.3796.
4
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.HOX 基因表达可预测急性髓系白血病对 BCL-2 抑制的反应。
Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8.
5
Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.将 BCL2 抑制剂 Venetoclax 与 PI3K 抑制剂 Bimiralisib 联合用于治疗 IDH2 和 FLT3 突变的急性髓系白血病的理由。
Int J Mol Sci. 2022 Oct 20;23(20):12587. doi: 10.3390/ijms232012587.
6
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.异柠檬酸脱氢酶1和2突变在急性髓系白血病中诱导对BCL-2的依赖性。
Nat Med. 2015 Feb;21(2):178-84. doi: 10.1038/nm.3788. Epub 2015 Jan 19.
7
IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour.IDH1/2 突变与 BCL-2 依赖性：AML 盔甲上的意外裂痕。
Cancer Cell. 2015 Mar 9;27(3):323-5. doi: 10.1016/j.ccell.2015.02.013.
8
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.采用维奈托克和去甲基化药物治疗的异柠檬酸脱氢酶1/2（IDH1/2）突变急性髓系白血病（AML）患者中微小残留病（MRD）的反应模式及影响
Blood Cancer J. 2023 Sep 21;13(1):148. doi: 10.1038/s41408-023-00915-6.
9
[Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report].[维奈克拉联合阿扎胞苷治疗复发的NPM1/IDH1突变型急性髓系白血病患者实现持久分子缓解：一例报告]
Zhonghua Xue Ye Xue Za Zhi. 2022 Feb 14;43(2):166. doi: 10.3760/cma.j.issn.0253-2727.2022.02.017.
10
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. Venetoclax 单药治疗对低甲基化药物难治性继发性 AML 且高表达 BCL-2 和/或 BIM 患者具有持久缓解作用。
Eur J Haematol. 2019 May;102(5):437-441. doi: 10.1111/ejh.13218. Epub 2019 Feb 28.

引用本文的文献

1
[Chinese expert consensus on prevention and treatment of immunotherapeutic and molecular targeted agents-related infections in patients with hematological malignancies (2025)].《血液系统恶性肿瘤患者免疫治疗及分子靶向药物相关感染防治中国专家共识（2025年版）》
Zhonghua Xue Ye Xue Za Zhi. 2025 Jan 14;46(1):18-30. doi: 10.3760/cma.j.cn121090-20241114-00451.

本文引用的文献

1
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.烟酰胺代谢介导复发性急性髓系白血病干细胞对 Venetoclax 的耐药性。
Cell Stem Cell. 2020 Nov 5;27(5):748-764.e4. doi: 10.1016/j.stem.2020.07.021. Epub 2020 Aug 20.
2
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
3
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.
单核细胞亚克隆赋予急性髓系白血病患者对 Venetoclax 为基础治疗的耐药性。
Cancer Discov. 2020 Apr;10(4):536-551. doi: 10.1158/2159-8290.CD-19-0710. Epub 2020 Jan 23.
4
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.TP53 凋亡网络是 AML 细胞中对 BCL2 抑制产生耐药的主要介质。
Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2.
5
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.急性髓系白血病中的微小残留病：来自欧洲白血病网微小残留病工作组的共识文件。
Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12.
6
Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.老年急性髓系白血病具有独特的基因和表观遗传特征。
Leukemia. 2017 Jul;31(7):1640-1644. doi: 10.1038/leu.2017.109. Epub 2017 Apr 3.
7
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
8
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.异柠檬酸脱氢酶1和2突变在急性髓系白血病中诱导对BCL-2的依赖性。
Nat Med. 2015 Feb;21(2):178-84. doi: 10.1038/nm.3788. Epub 2015 Jan 19.
9
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.急性髓系白血病及其他髓系恶性肿瘤中的DNMT3A和IDH突变：与预后的关联及潜在治疗策略
Leukemia. 2014 Sep;28(9):1774-83. doi: 10.1038/leu.2014.124. Epub 2014 Apr 4.
10
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.(R)-2-羟基戊二酸足以促进白血病发生，其作用是可逆的。
Science. 2013 Mar 29;339(6127):1621-5. doi: 10.1126/science.1231677. Epub 2013 Feb 7.